Pinnacle Associates Ltd. Increases Holdings in Amgen Inc. $AMGN

Pinnacle Associates Ltd. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% in the third quarter, HoldingsChannel reports. The firm owned 62,683 shares of the medical research company’s stock after buying an additional 2,556 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Amgen were worth $17,689,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rathbones Group PLC grew its position in shares of Amgen by 1.5% in the 3rd quarter. Rathbones Group PLC now owns 13,129 shares of the medical research company’s stock worth $3,705,000 after buying an additional 193 shares during the last quarter. Vinva Investment Management Ltd raised its holdings in shares of Amgen by 21.5% during the third quarter. Vinva Investment Management Ltd now owns 44,908 shares of the medical research company’s stock valued at $12,303,000 after acquiring an additional 7,958 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Amgen by 6.2% during the third quarter. Parallel Advisors LLC now owns 10,407 shares of the medical research company’s stock valued at $2,937,000 after acquiring an additional 610 shares in the last quarter. CreativeOne Wealth LLC lifted its stake in Amgen by 3.7% in the third quarter. CreativeOne Wealth LLC now owns 15,904 shares of the medical research company’s stock worth $4,488,000 after acquiring an additional 566 shares during the period. Finally, Natixis Advisors LLC boosted its holdings in Amgen by 0.7% in the third quarter. Natixis Advisors LLC now owns 341,057 shares of the medical research company’s stock valued at $96,246,000 after acquiring an additional 2,403 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Mizuho boosted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Cantor Fitzgerald lifted their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Scotiabank assumed coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. DZ Bank increased their price target on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $354.17.

Amgen Stock Up 0.5%

Shares of NASDAQ:AMGN opened at $369.53 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a fifty day simple moving average of $353.26 and a two-hundred day simple moving average of $322.80. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The stock has a market capitalization of $199.20 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 3.67 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.